GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout -- HBSS

GRAIL, Inc. lost over $2.2 billion in market capitalization on February 20, 2026, after its NHS-Galleri trial failed to meet its primary endpoint for early cancer detection. A securities class action lawsuit alleges the company misled investors about the trial's design and likelihood of success, claiming GRAIL had internal information suggesting three years would be insufficient for the trial but expressed high confidence anyway. The stock plunged over 50% following the announcement.